Amgen Inc. reports $8.62 billion revenue for quarter ended March 31, 2026, up 5.8%
Amgen Inc. reported revenue of $8.62 billion for the quarter ended March 31, 2026, an increase of 5.8% from the same quarter a year earlier ($8.15 billion).
For the same period it posted net income of $1.82 billion, up 5.1%, or $3.34 per diluted share (3.20 a year earlier).
That is a net margin of 21.1%.
On Sanad's AAOIFI Standard 21 screen, Amgen Inc. is currently compliant: interest-bearing debt is 21.8% of market capitalisation (limit 30%), and impure income is 1.1% of revenue (limit 5%).
Is Amgen Inc. halal?
See the full AAOIFI screening of Amgen Inc.
See the full AAOIFI screening of Amgen Inc.
Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.